Many drugs are approved after limited clinical trials, and it’s only after they’re on the market—sometimes quite awhile after--that problems surface.

Early warning on those problems is possible with relatively simple data-mining techniques similar to what Google uses, according to Nigam Shah, assistant professor of biomedical informatics at Stanford University, who will be presenting a study at HIMSS demonstrating the impact that big data analytics can have on drug surveillance.

Register or login for access to this item and much more

All Health Data Management content is archived after seven days.

Community members receive:
  • All recent and archived articles
  • Conference offers and updates
  • A full menu of enewsletter options
  • Web seminars, white papers, ebooks

Don't have an account? Register for Free Unlimited Access